NCT03941431 is a Phase 2 clinical trial of Jueyin granules in Plaque Psoriasis, sponsored by Shanghai Yueyang Integrated Medicine Hospital.

Who is sponsoring NCT03941431?

NCT03941431 is sponsored by Shanghai Yueyang Integrated Medicine Hospital.

What drugs are being tested in NCT03941431?

Interventions in NCT03941431: Jueyin granules, moving cupping therapy, NB-UVB therapy, Jueyin placebo granules, moving cupping placebo therapy, NB-UVB placebo phototherapy.

What condition does NCT03941431 study?

NCT03941431 studies Plaque Psoriasis.

Is NCT03941431 still recruiting?

NCT03941431 is currently status unknown. Last updated 8 May 2019.

Last reviewed 2019-05-08 · How we verify

NCT03941431

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Sequential Treatment of Psoriasis With Integrated Traditional Chinese and Western Medicine

Status unknown Phase 2 Last updated 8 May 2019

What this trial tests

Phase 2 trial testing Jueyin granules in Plaque Psoriasis in 378 participants. Status unknown.

Timeline

1 June 2019

Primary endpoint
31 December 2021

31 December 2021

Quick facts

Lead sponsor	Shanghai Yueyang Integrated Medicine Hospital
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	378
Start date	1 June 2019
Primary completion	31 December 2021
Estimated completion	31 December 2021
Sites	6 locations across China

Drugs / interventions tested

Jueyin granules — full drug profile →
moving cupping therapy
NB-UVB therapy
Jueyin placebo granules
moving cupping placebo therapy
NB-UVB placebo phototherapy

Conditions studied

Plaque Psoriasis — all drugs for Plaque Psoriasis →

Sponsor

Shanghai Yueyang Integrated Medicine Hospital

Who can join

Adults 18 to 65, any sex, with Plaque Psoriasis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study was to explore intervention time of Chinese medicine and specification of a sequential treatment plan for severe psoriasis with Chinese and Western medicine.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Our Choice: study protocol for a randomized controlled trial for optimal implementation of psoriasis treatment by the integration of Chinese and western medicine.
Sun X, Zhou X, Wei Y, Yang W, et al · · 2020 · cited 7× · PMID 32228720 · DOI 10.1186/s13063-020-4209-3
Antimicrobial and Anti-Infective Potential of Herbal Creams in Dermatology: Efficacy, Safety, and Challenges in Skin Infection Management.
Brar GS, Nandy SK, Sharma A, Siddiqui AJ, et al · · 2025 · PMID 41362433 · DOI 10.2147/idr.s565852
A Randomized Controlled Trial for the Optimal Implementation of Psoriasis Treatment by Integrating Chinese and Western Medicine.
Yu Y, Sun X, Hu R, Xia P, et al · · 2025 · PMID 40135074 · DOI 10.2147/ptt.s487536

Verify or expand the search:

Other trials of Jueyin granules

Trials testing the same drug.

NCT03961230 — Oral Chinese Herbal Medicine for Psoriasis Vulgaris With Blood Heat Syndrome · Phase 2 · unknown

Other recruiting trials for Plaque Psoriasis

Currently open trials in the same condition.

NCT07357831 — A Phase III Trial To Evaluate The Efficacy And Safety Of MC2-01 Cream Compared To CAL/BDP Gel and Vehicle In Plaque Psor · Phase 3 · recruiting
NCT07250802 — A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis · Phase 3 · recruiting
NCT06979453 — A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants Wit · Phase 3 · recruiting
NCT07234591 — A Study to Evaluate Effectiveness and Safety of a TYK2 Inhibitor in Subjects With Moderate to Severe Plaque Psoriasis · NA · recruiting
NCT07116967 — Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK) · Phase 3 · recruiting

Other Shanghai Yueyang Integrated Medicine Hospital trials

Trials by the same sponsor.

NCT07434076 — Cross-Sectional Study for an Ocular Imaging-Based Predictive Model of Inflammatory Skin Diseases Grounded in Traditional · not yet recruiting
NCT07351448 — Research on the Extraction of Tongue and Facial Diagnosis Features of Psoriasis Vulgaris in Traditional Chinese Medicine · not yet recruiting
NCT07003386 — Exploration of the Efficacy and Mechanism of Galantamine (an Extract From Lycoris Aurea) in Treating Ischemic Stroke · Phase 2, PHASE3 · recruiting
NCT06922565 — Efficacy of Acupuncture in the Treatment of Moderate-to-severe Atopic Dermatitis · NA · not yet recruiting
NCT06790940 — Construction of a Psoriasis and Psoriatic Arthritis Diagnostic Model Based on Multidimensional Nail Information · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03941431 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai Yueyang Integrated Medicine Hospital
Last refreshed: 8 May 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03941431.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing